Guggenheim Raises BeOne Medicines Stock Price Target on Revenue Beat
Guggenheim Raises BeOne Medicines Stock Price Target on Revenue Beat THE MONEYWISE JOURNAL · finance · Thursday, August 06, 2026 The investment firm now predicts a higher stock price for BeOne Medicines, reflecting the company's recent financial performance. By MoneyWise Guide Guggenheim has increased its stock price target for BeOne Medicines, following the company's revenue beat. The investment firm now predicts a higher stock price for BeOne Medicines, reflecting the company's recent financial performance. Key Takeaways Key Takeaways Guggenheim has raised its stock price target for BeOne Medicines. The investment firm's decision follows the company's revenue beat. BeOne Medicines' financial performance has led to the increased stock price target. Quick Facts Metric Value Why it matters Stock Price Target Increased by Guggenheim Reflects BeOne Medicin...